Cardinal Health, Inc. – Consensus Indicates Potential -1.5% Downside

DirectorsTalk Interviews

Cardinal Health, Inc. with ticker code (CAH) have now 13 analysts covering the stock. The analyst consensus points to a rating of ‘Hold’. The range between the high target price and low target price is between 80 and 56 and has a mean target at 69.54. With the stocks previous close at 70.63 this would indicate that there is a downside of -1.5%. The day 50 moving average is 62.01 while the 200 day moving average is 56.08. The market cap for the company is $19,046m. Visit the company website at: https://www.cardinalhealth.com

The potential market cap would be $18,752m based on the market concensus.

Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe, and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. The company was incorporated in 1979 and is headquartered in Dublin, Ohio.

Share on:

Latest Company News

GCP Infrastructure reports 8.0% portfolio yield and stronger balance sheet

GCP Infrastructure Investments has reported a 98.60 pence net asset value, portfolio valuation of £810.4 million and further debt and asset sale updates.

Plus500 expands US trading offering with new Single Stock Futures

Plus500 has launched Single Stock Futures in the US, broadening customer access to CME Group-listed contracts and leading US stocks.

Clarkson reports record first-half profit and raises interim dividend

Clarkson Plc reported record first-half profit, lifted interim dividend and said full-year performance is expected to be materially ahead of market expectations.

Ilika plc reaches a commercial turning point as new markets emerge for Stereax and Goliath (video)

Dr Tom McColm of Morphose Capital Partners explains why the company may be approaching an important commercial inflection point.

Alien Metals notes start of 8,300m West Pilbara drill program

Alien Metals notes GreenTech has started an 8,300 metre drill programme at Whundo and Munni Munni in Western Australia.

HICL Infrastructure reports resilient performance and advances strategic evolution

HICL Infrastructure Plc reports portfolio performance in line with expectations, an additional Cross London Trains stake, and reaffirmed dividend guidance.

    Search